CheckMate 77TPerioperative Nivolumab in Resectable Lung Cancer Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the CheckMate 77T trial, comparing the outcomes of perioperative nivolumab combined with … Read More
chemotherapy
PAPILLON Trial: Amivantamab in Lung Cancer
Year: 2023 Title: PAPILLON Subtitle: Amivantamab plus Chemotherapy in NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Type of Trial: A Randomized, Open-label Phase 3 trial Objective: To compare the efficacy, as demonstrated by progression-free survival (PFS), in … Read More
NSCLC Treatment: The AEGEAN Trial Breakthrough
“Innovations in NSCLC Treatment: The AEGEAN Trial Breakthrough” In recent years, the pursuit of more effective treatments for non-small-cell lung cancer (NSCLC) has been relentless. The AEGEAN trial of 2023, as reported in the esteemed New England Journal of Medicine … Read More
KEYNOTE 671 Trial: Perioperative Pembrolizumab in Early-Stage NSCLC
KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant … Read More
KEYNOTE-826 Trial Summary: Pembrolizumab in Metastatic Cervical Cancer
2021 KEYNOTE-826 TRIAL Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer double-blind, phase 3, randomized controlled trial Objective: To assess whether adding pembrolizumab to platinum-based chemotherapy with or without bevacizumab would improve efficacy as compared with chemotherapy with or without … Read More